{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.3","upperLimit":"44.4","value":"40.15"},{"groupId":"OG001","lowerLimit":"44.6","upperLimit":"73.5","value":"65.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.1","upperLimit":"66.3","value":"53.90"},{"groupId":"OG001","lowerLimit":"16.1","upperLimit":"90.1","value":"64.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"78.2","value":"54.65"},{"groupId":"OG001","lowerLimit":"42.6","upperLimit":"101.0","value":"73.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.70","upperLimit":"63.70","value":"63.70"},{"groupId":"OG001","lowerLimit":"12.9","upperLimit":"66.6","value":"39.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.40","upperLimit":"65.40","value":"65.40"},{"groupId":"OG001","lowerLimit":"54.80","upperLimit":"54.80","value":"54.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 11"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants were administered 2.5 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation"},{"description":"Participants were administered 3.4 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG001","title":"Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"EOI post belantamab mafodotin dose on Day 1 of Cycle 1, Cycle 2, Cycle 5, Cycle 8, and Cycle 11","title":"Part 1 - C-EOI for Total mAb","type":"SECONDARY","unitOfMeasure":"ug/mL"}